CS
INFI

Credit Suisse’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Credit Suisse’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-25,000
Closed -$297K – 4843
2014
Q1 		$297K Buy
25,000
+13,000
+108% +$174K ﹤0.01% 4116
2013
Q4 		$166K Buy
+12,000
New +$169K ﹤0.01% 4383

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Credit Suisse's INFI Position: Q1 2017 in Review

Credit Suisse sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2017, closing a stake of 27,252 shares — an estimated $37K sold.

Credit Suisse first reported a position in INFI in Q2 2013 and held it in 15 quarters. The position peaked at $5.49M in Q1 2014. 80 funds tracked by Wall St. Rank hold INFI as of Q1 2017.

  • Credit Suisse reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Credit Suisse sold 27,252 Infinity Pharmaceuticals, Inc. shares in Q1 2017, an estimated $37K.
  • Credit Suisse first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
  • Credit Suisse's Infinity Pharmaceuticals, Inc. position peaked at $5.49M in Q1 2014.
  • 80 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2017.

Based on Credit Suisse's 13F filing for Q1 2017, filed 15 May 2017.